North America Meningococcal Vaccine Market By Brand (Bexsero, Trumenba, Nimenrix, Menactra, Menveo and Other Brands), By Type (Bivalent, Quadrivalent and Other Types), By Age Group (Infants (0 to 2 years) and Children (2 years & above)), By Country, Indus

North America Meningococcal Vaccine Market By Brand (Bexsero, Trumenba, Nimenrix, Menactra, Menveo and Other Brands), By Type (Bivalent, Quadrivalent and Other Types), By Age Group (Infants (0 to 2 years) and Children (2 years & above)), By Country, Industry Analysis and Forecast, 2020 - 2026

The North America Meningococcal Vaccine Market would witness market growth of 7.8% CAGR during the forecast period (2020-2026).

Meningococcal meningitis is one of the rarest bacterial infections of the brain but it is potentially devastating in nature. Despite the advancement in the healthcare sector, still more R&D is required to be done as this disease can kill the host in a very short span. One out of 10 meningococcal meningitis patients expire from the disease, and about 15% of the survivors may suffer from some deadly complications, such as brain damage, amputation, or/and deafness.

The first attempt for the development of vaccines against meningitis was taken in the early 1900s and it had variable degrees of success. For the first time in the 1930s, a safe, stable, and effective vaccines were developed against pneumococcal meningitis, and following this in the 1960s, vaccines against meningococcal meningitis produced. Since then, researchers are focused on creating more effective and efficient vaccines against the numerous bacterial that causes meningitis.

Still, there is no single vaccine which is capable of fighting all forms of meningitis, that is why over past few years, research, and development for potential vaccines has grown considerably. There is notable decline in the occurrence of bacterial meningitis, 90% of the reduction in the disease is due to the increasing use of vaccination.

Meningococcal vaccines are perceiving a significant demand in line with a prominent increase in routine immunization. Increasing use of meningococcal vaccines for immunizing special risk groups, such as travellers, or military personnel is fuelling gains in the market.

Based on Brand, the market is segmented into Bexsero, Trumenba, Nimenrix, Menactra, Menveo and Other Brands. Based on Type, the market is segmented into Bivalent, Quadrivalent and Other Types. Based on Age Group, the market is segmented into Infants (0 to 2 years) and Children (2 years & above). Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Pfizer, Inc., Sanofi S.A., Walvax Biotechnology Co., Ltd., Bio-Manguinhos (Oswaldo Cruz Foundation), Bio-Med Pvt. Ltd., Chongqing Zhifei Biological Products Co., Ltd., Hualan Biological Engineering, Inc., Incepta Pharmaceuticals Ltd. and Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.)

Scope of the Study

Market Segments covered in the Report:

By Brand

  • Bexsero
  • Trumenba
  • Nimenrix
  • Menactra
  • Menveo
  • Other Brands
By Type
  • Bivalent
  • Quadrivalent
  • Other Types
By Age Group
  • Infants (0 to 2 years)
  • Children (2 years & above)
By Country
  • US
  • Canada
  • Mexico
  • Rest of North America
Companies Profiled
  • GlaxoSmithKline PLC (GSK)
  • Pfizer, Inc.
  • Sanofi S.A.
  • Walvax Biotechnology Co., Ltd.
  • Bio-Manguinhos (Oswaldo Cruz Foundation)
  • Bio-Med Pvt. Ltd.
  • Chongqing Zhifei Biological Products Co., Ltd.
  • Hualan Biological Engineering, Inc.
  • Incepta Pharmaceuticals Ltd.
  • Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.)
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Meningococcal Vaccine Market, by Brand
1.4.2 North America Meningococcal Vaccine Market, by Type
1.4.3 North America Meningococcal Vaccine Market, by Age Group
1.4.4 North America Meningococcal Vaccine Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Recent Developments in Meningococcal Vaccine Market
Chapter 4. North America Meningococcal Vaccine Market by Brand
4.1 North America Bexsero Market by Country
4.2 North America Trumenba Market by Country
4.3 North America Nimenrix Market by Country
4.4 North America Menactra Market by Country
4.5 North America Menveo Market by Country
4.6 North America Other Brands Market by Country
Chapter 5. North America Meningococcal Vaccine Market by Type
5.1 North America Bivalent Market by Country
5.2 North America Quadrivalent Market by Country
5.3 North America Other Types Market by Country
Chapter 6. North America Meningococcal Vaccine Market by Age Group
6.1 North America Children (2 years & above) and Adults Market by Country
6.2 North America Infants(0 to 2 years) Market by Country
Chapter 7. North America Meningococcal Vaccine Market by Country
7.1 USA Meningococcal Vaccine Market
7.1.1 USA Meningococcal Vaccine Market by Brand
7.1.2 USA Meningococcal Vaccine Market by Type
7.1.3 USA Meningococcal Vaccine Market by Age Group
7.2 Canada Meningococcal Vaccine Market
7.2.1 Canada Meningococcal Vaccine Market by Brand
7.2.2 Canada Meningococcal Vaccine Market by Type
7.2.3 Canada Meningococcal Vaccine Market by Age Group
7.3 Mexico Meningococcal Vaccine Market
7.3.1 Mexico Meningococcal Vaccine Market by Brand
7.3.2 Mexico Meningococcal Vaccine Market by Type
7.3.3 Mexico Meningococcal Vaccine Market by Age Group
7.4 Rest of North America Meningococcal Vaccine Market
7.4.1 Rest of North America Meningococcal Vaccine Market by Brand
7.4.2 Rest of North America Meningococcal Vaccine Market by Type
7.4.3 Rest of North America Meningococcal Vaccine Market by Age Group
Chapter 8. Company Profiles
8.1 GlaxoSmithKline PLC (GSK)
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Approvals:
8.2 Pfizer, Inc.
8.2.1 Company Overview
8.2.1 Financial Analysis
8.2.2 Segmental and Regional Analysis
8.2.3 Recent strategies and developments:
8.2.3.1 Approvals:
8.3 Sanofi S.A.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Approvals:
8.4 Walvax Biotechnology Co., Ltd.
8.4.1 Company Overview
8.5 Bio-Manguinhos (Oswaldo Cruz Foundation)
8.5.1 Company Overview
8.5.2 Recent strategies and developments:
8.5.2.1 Partnerships, Collaborations, and Agreements:
8.6 Bio-Med Pvt. Ltd.
8.6.1 Company Overview
8.7 Chongqing Zhifei Biological Products Co., Ltd.
8.7.1 Company Overview
8.8 Hualan Biological Engineering, Inc.
8.8.1 Company Overview
8.9 Incepta Pharmaceuticals Ltd.
8.9.1 Company Overview
8.10. Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.)
8.10.1 Company Overview
8.10.2 Recent strategies and developments:
8.10.2.1 Product Launches and Product Expansions:

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook